MedImmune to close vaccines sites in California

Tuesday, July 17, 2012 02:55 PM

Gaithersburg, Md.-based MedImmune, the global biologics arm of AstraZeneca, is restructuring its infectious disease and vaccines research, development and operations, closing its Mountain View, Calif., and Santa Clara, Calif., sites and consolidating its infectious disease and vaccines R&D to other existing sites. The changes are expected to be completed in 2014.

MedImmune's Hayward, Calif., site will remain open with additional capabilities invested in it.

MedImmune said the changes will enhance innovation across its therapeutic areas and improve alignment with other areas of product development while reducing the fixed costs associated with the sites.

The company estimates that approximately 300 positions will be affected. Of those, approximately 100 positions will move to other MedImmune locations. Worldwide, MedImmune has approximately 3,500 employees.

In February 2012, AstraZeneca announced an efficiency program to improve productivity, foster innovation and strengthen the company's commercial, operations and R&D capabilities, which runs through 2014.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs